RevvityLTS:0KHE 75 FCF Yield % is 3.88 as of Jul. 05, 2026, which is 1% above its 10-year median of 3.84. GuruFocus rates LTS:0KHE with a GF Score™ of 75/100 and a GF Value™ of $119.43 (Fairly Valued). The stock has 11 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Revvity ranks better than 75.81% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
As of today, Revvity's Trailing 12-Month Free Cash Flow is $493 Mil, and Market Cap is $12,691 Mil. Therefore, Revvity's FCF Yield % for today is 3.88%.
The historical rank and industry rank for Revvity's FCF Yield % or its related term are showing as below:
LTS:0KHE'
s FCF Yield % Range Over the Past 10 Years
Min: -0.47 Med: 3.84 Max: 8.56
Current: 3.88
During the past 13 years, the highest FCF Yield % of Revvity was 8.56%. The lowest was -0.47%. And the median was 3.84%.
LTS:0KHE's FCF Yield % is ranked better than 75.81% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.43
vs LTS:0KHE: 3.88
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Revvity FCF Yield % Related Terms
Revvity FCF Yield % Historical Data
* Premium members only.
The historical data trend for Revvity's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0KHE vs ICLR, CRL, MEDP: FCF Yield % Comparison
For the Diagnostics & Research subindustry, Revvity's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Revvity FCF Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Revvity's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Revvity (LTS:0KHE) has a FCF Yield % of 3.88 as of Jul. 05, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Revvity and its competitors. This is near median its historical median of 3.84. According to the industry distribution chart, Revvity ranks #52 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 24.2%.
Is Revvity's FCF Yield % too high?
Revvity's current FCF Yield % of 3.88 is near median its 10-year median of 3.84. Based on the distribution chart, Revvity ranks #52 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Revvity has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Revvity's FCF Yield % compare to ICLR and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Revvity ranks #52 out of 215 companies for FCF Yield %. This places Revvity in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Medical Diagnostics & Research company?
A good FCF Yield % depends on the Medical Diagnostics & Research industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Revvity and its competitors. Revvity's current FCF Yield % is 3.88, which is near median its own 10-year median of 3.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Revvity stock overvalued right now?
Based on GuruFocus' analysis, Revvity (LTS:0KHE) is currently considered Fairly Valued. The stock's GF Value™ is $119.43, compared to a current price of $112.73 — trading 5.6% below its estimated fair value. The current FCF Yield % is 3.88, which is near median its 10-year median of 3.84. Revvity's overall GF Score™ is 75/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Revvity (LTS:0KHE), the current FCF Yield % is 3.88 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Revvity (LTS:0KHE) Overvalued in 2026?
Based on GuruFocus' analysis, Revvity stock appears to be undervalued.
The current stock price of $112.73 is trading 5.6% below its estimated GF Value™ of $119.43.
GuruFocus considers Revvity to be Fairly Valued.
Key valuation signals for LTS:0KHE:
FCF Yield %: 3.88 (near median its 10-year median of 3.84)
GF Value™: $119.43 vs. price of $112.73 (5.6% below fair value)
No single metric tells the full story. See the LTS:0KHE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
75GF Score
Get the complete analysis for LTS:0KHE
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0KHE has been successfully added to your 
